Answers are grounded in this paper and cite their sources.
PURPOSE: Monoclonal antibody therapies are often dosed using real body weight (RBW) to theoretically minimize inter-patient variability in drug distribution and elimination. However, pharmacokinetic modeling suggests that monoclonal antibodies primarily distribute to plasma and extracellular fluid compartments, which increase less than proportionally with excess body weight. Intravenous teprotumumab is currently administered using RBW-based dosing, but the impact of deviations from ideal body weight (IBW) on treatment response or adverse effects remains unclear. METHODS: A retrospective cohort of 95 patients treated with teprotumumab for Thyroid Eye Disease (TED). AEs were graded with Common Terminology Criteria for Adverse Events (CTCAE); high-grade was defined as grade ≥2. An IBW multiple (IBWM) for each patient was derived from RBW/IBW. Proptosis improvement was the millimeters reduction in Hertel exophthalmometry of the worse eye. Associations with IBWM were assessed using logistic and linear regression adjusted for age and diabetes. RESULTS: Median IBWM was 1.30 (range 0.84-2.98). Grade ≥1 AEs occurred in 86.3% and grade ≥2 in 30.5%. Higher IBWM was associated with greater odds of grade ≥2 AEs (adjusted OR 7.0, 95% CI 1.6-30.8; p = 0.010) and grade ≥2 AEs excluding hyperglycemia (adjusted OR 5.3, 95% CI 1.4-24.3; p = 0.020), but not with proptosis improvement (β ≈ 0.08 mm; p = 0.89). No patient at or below ideal body weight (IBWM ≤ 1; n = 7) experienced a grade ≥2 AE. CONCLUSIONS: Higher RBW dose intensity was associated with more high-grade toxicity without greater proptosis benefit. These findings suggest that RBW dosing may expose overweight patients to increased toxicity and support investigation of alternative dosing strategies for teprotumumab.
No takes yet. Share an insight, caveat, or question.
Cherkas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: